ACHV · Achieve Life Sciences, Inc.

This filing represents a pivotal strategic and financial inflection point for Achieve Life Sciences, combining a substantial capital raise with top-level leadership transition and board refreshment — all timed around the imminent FDA decision on cytisinicline. The $180 million private placement provides critical runway to advance the Phase 3 e-cigarette cessation trial and commercial launch preparations, directly addressing the near-term PDUFA date of June 20, 2026 for smoking cessation. Structurally, the financing is highly contingent: the common warrants’ value hinges entirely on FDA approval timing and the company’s ability to secure stockholder approval for increased authorized shares — introducing execution risk that could dilute warrant holders if authorization lags. The appointment of Dr. Andrew Goldberg as CEO signals a deliberate shift toward commercial and investment expertise, given his background at Marshall Wace, Tarsus Pharmaceuticals, and Vivo Capital — suggesting prioritization of market readiness, capital discipline, and investor relations over pure R&D leadership. His equity package — representing 9.5% of fully diluted capitalization — underscores investor confidence and aligns long-term incentives with milestone-driven value creation, particularly the eight-tiered share price hurdles embedded in the CEO PSUs. The addition of three investor-designated directors (two immediate, one pending) further cements governance alignment with key financial stakeholders, while also triggering contractual obligations to nominate them through at least the 2027 annual meeting — effectively embedding investor influence into the board’s composition for the next two years. Collectively, these actions de-risk the near-term regulatory pathway while materially strengthening the company’s operational and financial foundation ahead of potential commercialization.